Literature DB >> 6766730

Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.

P Reiderer, G P Reynolds.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6766730      PMCID： PMC1429934          DOI： 10.1111/j.1365-2125.1980.tb04805.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

3.  Deprenyl is metabolized to methamphetamine and amphetamine in man.

Authors:  G P Reynolds; J D Elsworth; K Blau; M Sandler; A J Lees; G M Stern
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

4.  On the mode of action of L-deprenyl in the human central nervous system.

Authors:  P Riederer; M B Youdim; W D Rausch; W Birkmayer; K Jellinger; D Seemann
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

5.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

6.  Recent observations on the clinical pharmacology of (-)deprenyl.

Authors:  G M Stern; A J Lees; M Sandler
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

7.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

8.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321
  8 in total
  1 in total

1.  Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

Authors:  M Schachter; C D Marsden; J D Parkes; P Jenner; B Testa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.